Genforandringer som årsak til kjemoresistens ved primær brystkreft
- Prosjektnummer
- 910012
- Ansvarlig person
- Per Eystein Lønning
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Forskningsaktivitet
Study of suboptimum treatment response: lessons from breast cancer.
Lancet Oncol 2003 Mar;4(3):177-85.
PMID: 12623363
Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.
Eur J Cancer 2003 Mar;39(4):438-46.
PMID: 12751373
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Proc Natl Acad Sci U S A 2003 Jul;100(14):8418-23. Epub 2003 jun 26
PMID: 12829800
Clinical pharmacokinetics of aromatase inhibitors and inactivators.
Clin Pharmacokinet 2003;42(7):619-31.
PMID: 12844324
Development of aromatase inhibitors and their pharmacologic profile.
Am J Clin Oncol 2003 Aug;26(4):S3-8.
PMID: 12902871
X chromosome inactivation in cervical cancer patients.
Cancer Genet Cytogenet 2003 Oct;146(1):73-6.
PMID: 14499700
Pharmacokinetics of third-generation aromatase inhibitors.
Semin Oncol 2003 Aug;30(4 Suppl 14):23-32.
PMID: 14513434
Comparison between aromatase inhibitors and sequential use.
J Steroid Biochem Mol Biol 2003 Sep;86(3-5):275-82.
PMID: 14623521
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
Clin Cancer Res 2003 Nov;9(15):5582-8.
PMID: 14654539
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest